<DOC>
	<DOCNO>NCT01065441</DOCNO>
	<brief_summary>A Phase I/II study in-situ therapeutic cancer vaccine . Vaccines contain source antigen adjuvant . In study source tumor antigen come kill select tumor cryoablation ( kill use extreme cold ) adjuvant intentionally mis-matched immune cell ( AlloStim-TM ) engineer produce inflammatory cytokine .</brief_summary>
	<brief_title>Experimental Therapeutic Cancer Vaccine Created In-situ Patients With Stage II-Stage IV Cancer</brief_title>
	<detailed_description>This Phase I/II clinical study investigate optimal protocol indication create personalize anti-tumor vaccine within body patient cancer . The aim study evaluate safety administration anti-tumor effect vaccine protocol three separate step . Cancer patient generally present immune response cancer bias Th2 response , Th1 response consider necessary mediate anti-tumor immunity . The first step study consist multiple intradermal priming dos AlloStimTM . The aim step create Th1 immunity alloantigens AlloStimTM , thus increase number Th1 cell circulation . The second step protocol involve cryoablation select tumor lesion follow intratumoral AlloStimTM injection . The aim step generate tumor-specific CTL killer cell circulation . The final step intravenous infusion AlloStimTM . The aim step activate circulate Th1 cell , killer cell , natural killer cell . The aim step create inflammatory environment break-down ability tumor avoid anti-tumor immune response . In patient partial response recurrence disease , additional intravenous `` booster '' infusion utilized reactivate circulate immune cell .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>18 year old Stage IIIV include breast cancer , colorectal cancer , nonsmall cell lung cancer , ovarian gynecological cancer , prostate cancer , pancreatic GI cancer , melanoma , head neck cancer lymphoma/plasmacytoma . Measurable disease determine upon review abdominal and/or chest CT scan within 60 day evaluation study inclusion target tumor lesion cryoablation alcohol ablation locate liver , kidney , bone , lung , adrenal , pancreas , lymph node , skin , neck prostate deem accessible percutaneous access carcinomatosis malignant ascites malignant pleural effusion . When applicable , acceptable cryoablation procedure technique risk : target tumor ablation must adequate distance adjacent vasculature organ permit safe application cryoprobe ( generally , 2.5cm clearance cryoprobe vital structure bowel , inferior vena cava , aorta ) . The safety assessment cryoprobe placement make attend radiologist base imaging study . Life expectancy &gt; 90 day No bevacizumab ( Avastin® ) within 6 week plan cryoablation procedure ECOG status 02 No concurrent medication know interfere platelet function coagulation ( e.g. , aspirin , ibuprofen , clopidogrel , warfarin ) unless medication discontinue appropriate time period base drug halflife know activity ( e.g. , aspirin 7 day ) prior cryoablation procedure No low molecular weight heparin preparation unless discontinue 8 hour prior cryoablation At least 2 week since prior cytotoxic chemotherapy Absolute granulocyte count ≥ 1,200/mm3 Platelet count ≥ 100,000/mm3 PT/INR ≤ 1.5 INR correctable ≤ 1.5 PT/PTT correctable normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR monitor weekly prior cryoablation day assure INR stable . However , heparin warfarin must withhold prior cryoablation criterion meet . Hemoglobin ≥ 9 g/dL Creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 1.5 time normal Alkaline phosphatase ≤ 2.5 time normal ( ≤ 5 time normal liver involvement ) Aspartate aminotransferase ( AST ) ( SGOT ) ≤ 2.5 time ULN Alanine aminotransferase ( ALT ) ( SGPT ) ≤ 2.5 time ULN Not pregnant lactate Patients child bear potential must agree use adequate contraception No psychiatric addictive disorder condition , opinion investigator , would preclude study participation Study specific inform consent Taking anticoagulant medication concomitant medical condition ( unless safely discontinue cryoablation procedure ) Prior allogeneic bone marrow/stem cell solid organ transplant Chronic use ( &gt; 2 week ) great physiologic dos corticosteroid agent ( dose equivalent &gt; 10 mg/day prednisone ) within 30 day first day study drug treatment Topical inhale corticosteroid permit Concomitant active autoimmune disease ( e.g. , rheumatoid arthritis , multiple sclerosis , autoimmune thyroid disease , uveitis ) Prior experimental cancer vaccine treatment ( e.g. , dendritic cell therapy , heat shock vaccine ) Immunosuppressive therapy , include : cyclosporine , antithymocyte globulin , tacrolimus within 3 month study entry History blood transfusion reaction Known allergy bovine product Know allergy murine product Progressive viral bacterial infection All infection must resolve patient must remain afebrile seven day without antibiotic prior place study Cardiac disease symptomatic nature cardiac ejection fraction &lt; 45 % Symptomatic pulmonary disease FEV1 , FVC , DLCO ≤ 50 % predict History HIV positivity AIDS HBV and/or HCV positivity permit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>melanoma</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>GI cancer</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
</DOC>